Innovassynth Technologies is a research-driven specialty chemicals company that makes the complex molecular building blocks - protected nucleosides, amidites, and organometallic compounds - that global pharmaceutical and diagnostics companies need to develop new therapies. It was born from the 2025 merger of a listed investment shell with its operating associate, transforming a passive holding company into a direct operating business and giving public shareholders a direct stake in the manufacturing entity. The recurring approach is a single, integrated model: it takes a customer’s early-stage molecule, develops the process in its own R&D lab, scales it up across its multi-purpose manufacturing plants, and then supplies it at commercial volumes - all under one roof.
Business segments
A single engine with three interlocking service lines - custom research, life sciences intermediates, and specialty chemicals - all flowing through the same R&D-to-manufacturing backbone.
1. CRDMO services: the engine that pulls everything else
The company earns money by solving other companies’ chemistry problems - from a molecule on a napkin to tonnes in a reactor - and gets paid at every stage.
- Paid to think, not just to make - it offers Full Time Equivalent (FTE) and Fee for Service (FFS) arrangements where customers pay for dedicated scientist time and lab resources to develop a process, before any product is sold.
- One roof from lab to lorry - the Pune R&D centre with 60 fume hoods designs the process, and the Khopoli plant’s nine multi-purpose manufacturing units scale it up, so the customer never has to transfer technology between vendors.
- A pipeline that feeds itself - successful custom development projects naturally convert into commercial supply contracts, which is why the company tracks an open order book of roughly ₹28 Crores in this segment, including confirmed requirements from a large global chemical company.
- Riding a market that is shifting toward India - the global CDMO market was valued at USD 224.6 billion in 2023, but the Indian market is forecast to grow at nearly 15% annually, roughly double the global rate, as pharmaceutical companies look for lower-cost, high-skill alternatives.
2. Life sciences and nucleosides: the high-stakes niche
It makes the modified DNA and RNA building blocks that go into first-in-class therapies for diseases with no current treatment - a business where a single molecule can define a drug.
- The molecule is the medicine - the company supplies protected nucleosides and modified phosphonamidites, the chemical precursors used to manufacture therapeutic oligonucleotides (drugs made of short DNA or RNA strands) for clinical and commercial use.
- One of a handful globally - its ability to supply a wide range of these highly specialised molecules has made it one of the top few companies in the world engaged in this activity, serving pharmaceutical and diagnostics customers primarily in the USA and Europe.
- Backward integration is the margin lever - for regular products, the company works on making its own starting materials rather than buying them, and continuously improves its processes to boost yields, which strengthens its position against international competitors.
- Doubling down on demand - a capacity expansion is underway to double the life sciences output, aligned with growing CDMO demand, and the order book improved by approximately Rs 60 crore during the fourth quarter of FY26, reflecting continued customer demand.
3. Specialty chemicals: the wide-angle lens
It applies the same custom-synthesis skills to a broader canvas - making niche intermediates and organometallic compounds for industries from semiconductors to flavours.
- Chemistry that crosses industries - the business develops organometallic compounds and specialty intermediates for applications spanning pharmaceuticals, diagnostics, electronics, semiconductors, polymers, and flavours and fragrances.
- Niche means pricing power - by focusing on developing bespoke products for specific customers rather than competing on commodity chemicals, the business earns higher profit margins.
- Semiconductors are the new frontier - the company has received several development requests from major players for semiconductor materials, which are at different stages of process optimisation, and has also taken on scale-up projects for polyolefins production.
- A smaller but growing order book - the open order book for specialty chemicals was roughly ₹22 Crores as of the fourth quarter of FY26, reflecting the early-stage, development-heavy nature of this pipeline.
Manufacturing and R&D backbone
A 60-acre integrated site with nine plants, 250 kilolitres of reaction capacity, and a Pune R&D lab - the physical platform that makes all three service lines possible.
- Scale without rigidity - the Khopoli facility has eight units housing nine multi-purpose manufacturing plants with reactor sizes ranging from 50 litres to 10,000 litres, built in various materials of construction (stainless steel, glass-lined, and glass reactors) so it can handle everything from grams to tonnes.
- Chemistry that handles the hard stuff - the plant’s capabilities span oxidation, reduction, Friedel-crafts, Diels Alder, Suzuki coupling, and cryogenic reactions using reagents like Grignard and n-BuLi, which require temperatures far below zero.
- The brain is in Pune - the R&D facility houses 60 fume hoods and a dedicated analytical lab, staffed by over 50 scientists including more than 10 PhDs, who perform custom development under FTE and FFS contracts.
- Imported inputs, single-state risk - roughly 40% of raw materials are imported, and both the plant and the R&D centre are in Maharashtra, creating a dependency on a single state’s infrastructure and regulatory environment.
Group structure and partners
A listed operating company with no subsidiaries, formed by merging the business into the shell - promoter-held at nearly 74%, with a rights issue on the horizon.
- The merger that created the company - the unlisted operating entity Innovassynth Technologies (India) Limited (incorporated in 2001) was absorbed into the listed investment company Innovassynth Investments Limited (incorporated in 2008) under a Scheme of Merger effective 19 December 2025, with a 1:1 share exchange ratio.
- Post-merger ownership - following the allotment of roughly 4.75 crore new shares to the operating company’s shareholders, promoter and promoter group holding stands at 73.70%, with public shareholders at 26.30%.
- No subsidiary web - the company has no subsidiaries, so all operations, assets, and cash flows sit directly in the listed entity.
- Funding the next leg - in March 2026, the board approved a proposal to raise up to ₹70 Crores through a rights issue of equity shares, signalling an intent to fund expansion without adding debt.